By Adria Calatayud

 

e-Therapeutics PLC said Friday that it expects to receive payments from Galapagos NV after meeting two milestones under a collaboration agreement between the two companies.

U.K.-based e-Therapeutics, a provider of technology services for drug discovery, said the collaboration--which seeks to identify new therapeutic approaches for the treatment of idiopathic pulmonary fibrosis and other fibrotic conditions--has remained on schedule despite the coronavirus pandemic.

Under the terms of its agreement with Galapagos, e-therapeutics is eligible to receive additional milestone payments, it said.

 

Write to Adria Calatayud at adria.calatayud@dowjones.com

 

(END) Dow Jones Newswires

April 23, 2021 03:08 ET (07:08 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.